A porous metal–organic framework (MOF) based on Zn(II) metal nodes was prepared via reaction of rigid V-shaped ligand 2,6-di(2′,5′-dicarboxylphenyl)pyridine (H₄L) along with Zn(NO₃)₂·6H₂O in water and DMF mixed solvent, and its chemical formula was [Zn₃(L)(OH)₂(H₂O)₄](DMF)₅ (1). The results show that the obtained activated 1a has catalytic activity for aromatic aldehydes cyanation under the existence of the trimethylsilyl cyanide, thus providing trimethylsilyl cyanohydrin in the form of shape along with size selection. In addition, a feasible synergistic mechanism of 1a for cyanosilylation of aldehyde also has been put forward. Furthermore, the treatment function of the compound on bladder cancer cells was assessed. The reverse transcription-polymerase chain reaction (PT-PCR) was carried out to determine cyclindromatosis (CYLD) and miR-130 relative expression in bladder cancer cells after the combine therapy. Besides, the mechanism of the compound was explored, by evaluating the level of autophagic programed cell death by western blot.

通过刚性V形配体2,6-二（2'，5'-二羧基苯基）吡啶（H ₄ L）与锌的反应，制备了基于Zn（II）金属节点的多孔金属-有机骨架（MOF）（NO ₃）₂ ·6H ₂ O在水中与DMF混合的溶剂，其化学式为[Zn ₃（L）（OH）₂（H ₂ O）₄ ]（DMF）₅（1）。结果表明，得到的活化的1a在三甲基甲硅烷基氰化物的存在下，对芳族醛的氰化反应具有催化活性，因此提供了形状和尺寸选择形式的三甲基甲硅烷基氰醇。此外，还提出了一种可行的1a协同作用，用于醛的氰基硅烷化。此外，评估了该化合物对膀胱癌细胞的治疗功能。联合治疗后，进行逆转录-聚合酶链反应（PT-PCR），以确定细胞周期周期增生（CYLD）和miR-130在膀胱癌细胞中的相对表达。此外，通过蛋白质印迹评估自噬程序性细胞死亡的水平，探索了该化合物的机理。